title: Doxazosin oral intake therapy to relieve stent - related urinary symptoms and pain: a prospective, randomized, controlled study.
abstract: OBJECTIVE
  To assess the impact of Doxazosin Oral Intake Therapy on urinary symptoms and pain in patients with indwelling ureteral stents Patients and Methods: A total of 239 patients with ureteral stone-related hydronephrosis who underwent a double-J stent insertion after ureteroscopic lithotripsy were enrolled. Patients were randomized to receive doxazosin cotrolled release 4 mg once daily for 4 weeks or matching placebo. Patients completed the brief-form Chinese version Ureteric Stent Symptom Questionnaire (USSQ) and quality of life (QoL) score 2 weeks and 4 weeks after stent placement and 4 weeks after stent withdrawal. The analgesic use was also recorded during the stenting period.
  
  
  RESULTS
  Patients in Doxazosin Oral Intake Therapy group, in the first 2 weeks and second 2 weeks with the stent in situ, expressed significant lower daytime frequency (p=0.028 and p=0.038), nocturia (p=0.021 and p=0.008) and urgency (p=0.012 and p=0.014), respectively. Similarly, flank pain score, QoL score and analgesic use were also significant less in the stenting period. There was no significant difference in scores of urinary symptoms, pain and QoL during the post-stent period between two cohorts.
  
  
  CONCLUSIONS
  Doxazosin Oral Intake Therapy reduced stent-related urinary symptoms, pain and the negative impact on QoL.
authors: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
authors: Long
authors: L
authors: Zhang
authors: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.|Department of Urology, Jingmen No.1 People's Hospital, Jingmen, Hubei, China.
authors: Junping
authors: J
authors: Li
authors: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.|Department of Urology, Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China.
authors: Minjie
authors: M
authors: Pan
authors: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
authors: Weiwei
authors: W
authors: Han
authors: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
authors: Shucheng
authors: S
authors: Liu
authors: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
authors: Yajun
authors: Y
authors: Xiao
mesh_terms: D000284:Administration, Oral; D058668:Adrenergic alpha-1 Receptor Antagonists / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D017292:Doxazosin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008096:Lithotripsy / Q000379:methods; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy*; D011184:Postoperative Period; D011446:Prospective Studies; D011788:Quality of Life; D015607:Stents / Q000009:adverse effects*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D018666:Ureteroscopy / Q000009:adverse effects
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D017292:Doxazosin
keywords: Doxazosin; Lower Urinary Tract Symptoms; Quality of Life